Introduction: Ischemic stroke is characterized as a sudden neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause. This study was performed to determine the frequency of G20210A mutation in the prothrombin gene and its effectiveness on the incidence of ischemic stroke in the Erbil city of Kurdistan region, Iraq. Methods: A total of 50 patients with ischemic stroke was analyzed for the detection of prothrombin gene mutation (G20210A), using polymerase chain reaction (PCR), Restriction fragment length polymorphism (RFLP) with Hind III restriction enzyme. Results: We observed no evidence of an association between ischemic stroke and G20210A mutation in the prothrombin gene in this region. Conclusion: Our finding demonstrates that prothrombotic gene variant seems not to be linked to the incidence of ischemic stroke in Erbil region.
IntroductionIschemic stroke is sudden neurologic deficits that result from focal cerebral ischemia associated with permanent brain infarction. It is a major cause of disability and death worldwide which occurs as a result of atherothrombotic occlusion of large arteries; cerebral embolism; nonthrombotic occlusion of small, deep cerebral arteries; and proximal arterial stenosis with hypotension that decreases cerebral blood flow in arterial watershed zones.1 A multifunctional multimeric plasma glycoprotein von Willebrand factor (vWF), has long been known to be a key player in thrombus formation at sites of vascular damage, vWF act as a carrier protein for blood clotting FVIII and promotes platelet adhesion and aggregation at sites of vascular injury. The release of vWF is increased when endothelial cells are activated or damaged. Therefore, plasma vWF level is considered a marker of endothelial dysfunction, a condition that predisposes to atherosclerosis and thrombosis. Because of its direct role in hemostasis, and its indirect role as a marker of endothelial dysfunction, vWF is a potential risk indicator for cerebrovascular disease.2 Recent studies revealed that abnormal elevation of any or all lipids and/or lipoproteins which known as hyperlipidemia is considered a modifiable risk factors that play a crucial role in the pathogenesis of atherosclerosis and biological etiology of the ischemic stroke. Hyperlipidemia usually classified as either familial caused by specific genetic abnormalities, or acquired when resulting from endocrine, renal or hepatic diseases. 4 Deposition of cholesterol and cholesteryl ester from the plasma lipoproteins into Background and objective: Ischemic stroke is classically characterized as a neurological deficit attributed to an acute focal injury of the central nervous system by a vascular cause, it occurs as a result of obstruction by a blood clot (thrombus) or plugs within a blood vessel supplying blood to the brain. In this study, we investigated the association of von Willebrand factor-antigen and serum lipids with ischemic stroke. Methods: The following retrospective study was conducted on 138 participants; 88 patients with ischemic stroke and 50 healthy controls. Results: In crude analyses, Plasma von Willebrand factor antigen, fasting serum Total cholesterol, Triglycerides and LDL-C were significantly higher in patients with ischemic stroke than in controls (P <0.001, P <0.001, P = 0.003, P <0.001, respectively), while the difference in the level of serum HDL-C between patients with ischemic stroke and control was significantly lower (P = 0.023). Conclusion: These data suggest that von Willebrand factor, total cholesterol, triglycerides, LDL-C and HDL-C gives some contribution to stroke risk even in the elderly and that von Willebrand factor antigen and lipid profile assessment must be taken into account in estimating the individual risks of stroke.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.